CareDx, Inc. (CDNA) News
Filter CDNA News Items
CDNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDNA News Highlights
- CDNA's 30 day story count now stands at 2.
- Over the past 11 days, the trend for CDNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CDNA News From Around the Web
Below are the latest news stories about CAREDX INC that investors may wish to consider to help them evaluate CDNA as an investment opportunity.
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication AdherenceBRISBANE, Calif., December 19, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is joining forces with the National Foundation for Transplants (NFT) in offering its Transplant Pharmacy services to NFT patient members to help them manage the complexity of post-transplant medication adherence. |
How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72%The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
CareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call TranscriptCareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call Transcript November 8, 2023 CareDx, Inc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.38. Operator: Good day, everyone, and welcome to today’s CareDx Inc. Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity […] |
CareDx Reports Third Quarter 2023 ResultsBRISBANE, Calif., November 08, 2023--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended September 30, 2023. |
CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
CareDx to Report Third Quarter 2023 Financial ResultsBRISBANE, Calif., November 02, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern |
CareDx Announces CEO TransitionBRISBANE, Calif., November 01, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to th |
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual MeetingBRISBANE, Calif., October 17, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in San Antonio, Texas from October 16-20, 2023. |
Market Today: Tech Stocks Under Pressure, House Ousts McCarthy, and FTC Accuses Amazon of Price ...A report from Morgan Stanley identified over 80 stocks that could face technical pressure due to tax loss selling in the fourth quarter. In a historic move, the U.S. House of Representatives voted to remove Kevin McCarthy as speaker. The Federal Trade Commission (FTC) has accused Amazon (NASDAQ:AMZN) of developing a secretive algorithm to manipulate prices. |